Author: ingedesign

Sollis Therapeutics, Inc., an Ohio-based interventional pain therapeutics company, announced that the first patient was enrolled in the RePRIEVE-CM trial, a Phase 3 clinical trial evaluating the efficacy and safety of the extended release non-opioid, non-steroid clonidine micropellet for the treatment of sciatica pain.

Sollis Therapeutics’ CEO, Gregory Fiore, MD, will join the panel of speakers on November 14, 2018 at the BioOhio conference. This conference will highlight innovations in neuroscience research and technologies that are addressing the opioid crisis. This event will also feature an Alternatives to Opioids Tech Showcase.